
Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.
Supplements and Featured Publications
over 26 years ago
Participating Facultyover 26 years ago
Introductionover 26 years ago
The Impact of the New HEDIS Guidelines: Practical Considerationsover 26 years ago
Impact and Risks of Untreated Hypertension on Managed Careover 26 years ago
Closing Remarksover 26 years ago
CE Quizover 26 years ago
Selected Abstractsover 26 years ago
Bibliography





